Application deadline: 31/03/2019
Number of vacancies: 1 – 2
We seek one or two fellows interested in working in clinical and translational research within
our Phase I program. The successful candidate will be in charge of patients and clinical trials of
our Early Clinical Drug Development Group. The appointed individual will be mentored by one
of our Senior Consultants and will be involved in clinical trials, molecular prescreening, and
translational projects of our Research Unit for Molecular Therapy of Cancer (UITM) – “la Caixa”.
Development of Investigator Initiated Trials and projects will be highly encouraged, as well as
involvement in collaborative research with other VHIO groups.
The duration of the Fellowship will be between 1 – 2 years depending on previous experience
and the contract may be extended at a later date based on professional merit. Review of
applications will commence immediately and we hope to incorporate the fellow no later than
The appointed fellow will be board certified a medical oncology. The main focus of VHIO’s UITM
is developing targeted therapies against cancer which should also be of special interest to the
fellow. Prior experience in clinical research will be favorably considered. Since the fellow will be
involved with patients treated in Phase I trials, excellent communication skills in Spanish are
imperative. Good written and spoken English are required for communication with sponsor and
Please send a CV and cover letter to: firstname.lastname@example.org, including the reference
“23/2018” in the subject line of your email.
UITM is a dedicated unit for Phase I trials located within the Medical Oncology Department, the
Vall d´Hebron University Hospital (HUVH). Faithful to VHIO’s purely translational and
multidisciplinary research model, collaboration and connectivity between and among our
various tumor-specific units (Breast cancer, GI cancers, etc.), translational research groups and
core technologies including molecular oncology, is essential.
In addition to our expertise in early drug development and clinical trial design, we are also
involved in biomarker development (CTC, Pharmacodynamics, etc.), patient-derived xenografts,
and the molecular analysis of tumors for treatment selection. We have the necessary state-ofthe-
art facilities for translational research of excellence, with other VHIO groups focusing on
important areas including cancer stem cells, cell-signaling, resistance to targeted therapies,
cancer genomics, and molecular oncology.
General description of the site
The Vall d´Hebron University Hospital (HUVH) is one of the largest hospitals in Spain. Our
Medical Oncology Department, directed by Josep Tabernero, provides excellent patient care and
is involved in both basic and clinical research, with a clear focus on translational oncology. The
interaction between clinical research and laboratory investigation is paramount since it spurs
the development of research opportunities.
At our Research Unit for Molecular Therapy of Cancer (UITM) – “la Caixa”, we perform early
clinical studies (phase I trials) with novel therapeutics. The main focus is translating experimental
targeted treatment strategies to the clinical level for testing. Our main areas of interest include
first-in-human trials, novel combinations of targeted therapies and biomarker-driven studies.
Historically, the phase I Unit has steadily grow in breadth, scope and recognition, and has since
become one of the largest in Europe both in terms of dedicated space, as well as number of
trials and patients enrolled.
Under the leadership of Josep Tabernero, the Vall d’Hebron Institute of Oncology (VHIO),
created by José Baselga in 2006, has established itself as a comprehensive cancer center of
proven excellence internationally. It is thanks to Josep Tabernero’s directorship and VHIO’s
optimal organizational structure based on a purely multidisciplinary and translational model that
VHIO talents continue to anticipate and tackle the many unresolved questions in combatting
this multifaceted and heterogeneous disease.
Located within the Vall d’Hebron Barcelona Hospital Campus, our researchers closely
collaborate and interact with Vall d’Hebron physician-scientists. Translational science and
clinical research are therefore tightly connected which promotes superb interaction and
teamwork which, in turn, accelerates the bench-bedside-bed cycle of knowledge. This privileged
environment affords VHIO direct access to patients as well as the entire spectrum of oncology
professionals who care for them, and a second-to-none appreciation of how cancer science can
translate into more powerful, targeted treatments and better practice for the care of patients.
VHIO’s pioneering model and programs, coupled with its belief in combining strengths through
cross-border collaborations, continue to spur advances in reversing cancer resistance, halting
metastatic spread, and more effectively treating even the most undruggable tumor types.
VHIO’s translation toward precision oncology: http://www.vhio.net.